Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD on One-A-Day

This article was originally published in The Tan Sheet

Executive Summary

Bayer HealthCare should discontinue advertising claims stating that men can reduce their risk of prostate cancer by taking One-A-Day Men's Health Formula, the watchdog group concludes in a recent Case Report. Although Bayer cited Harvard Medical School studies linking lycopene to prostate health, ad claims conveyed a message that was "much broader than the evidence could support," NAD maintains. The ad depicts a fire chief who advises his coworkers to switch to One-A-Day Men's when he learns that "one in three men face prostate cancer." Bayer provided reasonable scientific evidence to support the link between lycopene and prostate health, NAD says, but the ad's "tone of concern" and backdrop "make it reasonable for consumers to take away a message that taking One-A-Day has a cancer preventive effect because it contains lycopene"...

You may also be interested in...



NAD Weight-Loss Claims Bulk Up In 2004; Whitening Cases Lose Luster

Nearly half of the National Advertising Division cases involving the OTC drug, dietary supplement and oral care markets thus far in 2004 were initiated by the watchdog group, and not brought forward by a competing company

Will AZ Legal Notice, Clotting Incidents Cloud Serum’s Fortunes?

AstraZeneca has sent a legal notice to Indian partner Serum Institute for non-delivery of COVID-19 vaccines. Will this and the entry of a new challenger, Sputnik V, in the Indian market affect Serum’s fortunes? Will the EMA and MHRA announcement on clotting incidents related to the AZ vaccine shrink demand for the partnered vaccine?

QUOTED. 13 April 2021. US FDA.

As medical organizations such as the Veterans Health Administration and Mayo Clinic are positioning themselves to become medical device manufacturers using 3D printing technologies, it opens challenges and opportunities. See what Mayo Clinic’s Sean McEligot said about it here.

Topics

UsernamePublicRestriction

Register

PS097117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel